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Abstract We report the isolation and characterization of a
novel human peptide with antimicrobial activity, termed LEAP-1
(liver-expressed antimicrobial peptide). Using a mass spectro-
metric assay detecting cysteine-rich peptides, a 25-residue
peptide containing four disulfide bonds was identified in human
blood ultrafiltrate. LEAP-1 expression was predominantly
detected in the liver, and, to a much lower extent, in the heart.
In radial diffusion assays, Gram-positive Bacillus megaterium,
Bacillus subtilis, Micrococcus luteus, Staphylococcus carnosus,
and Gram-negative Neisseria cinerea as well as the yeast
Saccharomyces cerevisiae dose-dependently exhibited sensitivity
upon treatment with synthetic LEAP-1. The discovery of LEAP-
1 extends the known families of mammalian peptides with
antimicrobial activity by its novel disulfide motif and distinct
expression pattern. ß 2000 Federation of European Biochem-
ical Societies. Published by Elsevier Science B.V. All rights
reserved.
Key words: Antimicrobial peptide; Liver; Hemo¢ltrate;
Cysteine-rich peptide
1. Introduction
Antimicrobial peptides are an important component of in-
nate immunity in many species, including plants, insects, ¢sh,
amphibians and mammals [1^3]. Although especially the latter
have a highly e⁄cient system of adaptive immunity, there is
growing evidence that in animals antimicrobial peptides such
as defensins [2,3], protegrins [4] and cathelicidins [5] represent
a considerable part of the immune system in the defense of
cellular pathogens. Antimicrobial peptides are predominantly
expressed in epithelial cells lining the respiratory, alimentary
and genito-urinary tract as well as in granules of circulating
phagocytes, and they exert their activity mainly by disrupting
the cell membranes of cellular pathogens [3,6^8]. This rather
unspeci¢c mode of action is suggested to be responsible for
the broad-spectrum activity of many peptide antibiotics. De-
spite their diverging e¡ects, most antimicrobial peptides share
common structural elements in being amphipathic and carry-
ing net positive charges at physiological pH due to basic ami-
no acid residues [1,7].
As many antimicrobial peptides contain multiple disul¢de
bonds, we intended to isolate small cysteine-rich peptides
from human blood ultra¢ltrate, which was shown earlier to
be a source of defensins [9]. Using a cysteine alkylation assay,
we report the isolation and characterization of a novel ex-
tremely cysteine-rich 25-residue peptide that was termed
LEAP-1 (liver-expressed antimicrobial peptide). By analysis
of the primary structure and the corresponding cloned
cDNA, we demonstrate that LEAP-1 is a novel peptide which
resembles other peptide antibiotics in that it exhibits compa-
rable structural elements and antimicrobial activity, but di¡ers
signi¢cantly in the predominant expression in liver.
2. Materials and methods
2.1. Isolation and structural characterization of LEAP-1
LEAP-1 was isolated during a comprehensive search for cysteine-
containing peptides in fractions from human blood ultra¢ltrate [10].
In brief, the cysteine content of a peptide is determined after reduction
of disul¢des and subsequent carboxamidomethylation of the resulting
free thiol groups inducing a de¢ned mass shift for each single cysteine
residue. 10 Wg of freeze-dried fractions were dissolved in 4-methylmor-
pholine (50 Wl, 200 mM, pH 8.3) and dithiothreitol (5 Wl, 400 mM)
was added. After incubation for 60 min at 45‡C, iodoacetamide (20 Wl,
500 mM) was added, and after a further 30 min at ambient temper-
ature, the samples were desalted by solid-phase extraction. Peptides
were eluted with 100 Wl 70% acetonitrile in 0.1% tri£uoroacetic acid
(TFA), and the fractions were subjected to MALDI-TOF mass spec-
trometry prior to and after carboxamidomethylation on a Voyager-
DE STR (PerSeptive Biosystems). LEAP-1 was identi¢ed as a peptide
with a molecular mass of 2789.8 Da and a content of eight cysteine
residues calculated from the resulting mass shift of +464.5 Da in the
alkylated fraction (Fig. 1). For puri¢cation of LEAP-1, a 10-mg ali-
quot of the corresponding peptide fraction was dissolved in 0.06%
TFA and separated in three reverse-phase HPLC steps. Final puri¢-
cation was performed on a C18 ODS-AQ column (4.6U250 mm,
5 Wm, 120 Aî , UV detection at 214/280 nm, YMC Europe, Scherm-
beck, Germany). NH2-terminal amino acid sequence analysis was
performed by Edman degradation using a Procise 494 sequencer
(PE Biosystems, Foster City, CA, USA).
2.2. Peptide synthesis
LEAP-1 was assembled on a preloaded Tentagel R Trt-Thr(tBu)
resin (Rapp Polymere, Tu«bingen, Germany) using standard Fmoc
chemistry and trityl-protected cysteines. The peptide was deprotected
and cleaved from the resin with a mixture of TFA, ethanedithiol and
water (94:3:3). After ¢ltration and precipitation with tert-butylmethyl-
ether, the reduced peptide obtained was puri¢ed by reverse-phase
HPLC on a Vydac C18 column (The Separations Group, Hesperia,
CA, USA). Fractions containing the product were identi¢ed using
electrospray mass spectrometry (ESIMS; Mr determined, 2797.5
Da; Mr calculated, 2797.3 Da) and analytical HPLC, and subjected
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to oxidation in phosphate bu¡er at pH 7.4. The fully disul¢de-bonded
peptide was then puri¢ed by reverse-phase HPLC (Vydac C18). Purity
was checked on a Nucleosil C18 PPN column (Macherey and Nagel,
Du«ren, Germany) and by capillary electrophoresis on a Beckman
P/ACE System 2000. Synthetic LEAP-1 coeluted and comigrated
with native LEAP-1 during reverse-phase HPLC and capillary elec-
trophoresis, respectively. The molecular mass of the product was de-
termined by ESIMS (Mr experimental 2789.5 Da; Mr calculated
2789.3 Da).
2.3. Antimicrobial activity
2.3.1. Radial di¡usion assay [11]. Bacterial cells in mid-logarith-
mic phase (500 Wl) were added to 100 ml of previously boiled 10 mM
sodium phosphate bu¡er (pH 7.2, 37‡C) containing 0.03% (w/v) tryp-
tic soy broth, 0.8% (w/v) NuSieve GTG agarose (FMC BioProducts,
Rockland, ME, USA) and 0.02% (v/v) Tween 20. Bacteria growing at
37‡C were plated with 0.2% type 1 agarose (w/v, low EEO, Sigma-
Aldrich) and 0.6% NuSieve agarose. The mixture was pipetted into
sterile Petri dishes and evenly spaced wells were obtained by punching
out gel cylinders with a diameter of 3 mm. After incubation of the
bacteria with synthetic LEAP-1 (1^11 Wg) for 18 h, growth inhibition
appeared as plain circular zones, and their diameters were determined
[12]. Synthetic casein-(16^57), a 42-residue peptide fragment of human
casein K-s1, was used as a negative control in order to exclude any
e¡ect due to contaminants derived from peptide synthesis procedures.
Experiments were carried out in duplicate. Water was used as addi-
tional negative control.
2.3.2. Determination of colony forming units (CFU). S. cerevisiae
was cultured overnight at 30‡C in YPD medium (1% yeast extract, 2%
peptone, w/v, pH 6.5). To obtain mid-logarithmic phase germs, cells
were subcultured at 1:100 for 3 h and harvested by centrifugation at
600Ug and 4‡C for 10 min. After washing of the pellets a dilution
containing approximately 2U106 cells/ml in 10 mM sodium phos-
phate bu¡er was prepared. Dry LEAP-1 (1^12.5 Wg) was then mixed
with 100 Wl of cell suspension and incubated for 2 h at 30‡C. Sub-
sequently, 10 Wl of this mixture was withdrawn and the reaction was
stopped by a 500-fold dilution with ice-cold sodium phosphate bu¡er,
and aliquots were manually spread on YPD agar plates. After 16 h at
30‡C, colonies were counted and inhibition percentiles were calcu-
lated. Three single experiments were carried out at least in triplicate.
An analogous procedure was performed with B. subtilis using LB
medium (pH 7.4).
2.4. Molecular biological standard methods and cDNA cloning
RNA extraction, cDNA ¢rst strand synthesis, polymerase chain
reaction (PCR), reverse transcription/polymerase chain reaction
(RT-PCR), and DNA £uorescence sequencing were performed as de-
scribed earlier [13^15]. LEAP-1-speci¢c cDNA fragments were ampli-
¢ed from human liver cDNA by means of standard RT-PCR methods
using the primers SN-2S (CCGCTTGCCTCCTGCTCCTCC-
TCCTCCTCG) and SN-6AS (CGATGACAGCAGCCGCAGCA-
GAAAATGCAG) derived from a LEAP-1 gene-containing sequence
(accession number AD000684, positions 31 400^34 200). Nested 3P-
and 5P-RACE PCR for ampli¢cation of LEAP-1 cDNA ends was
performed using Marathon-Ready human liver cDNA (Clontech,
Palo Alto, CA, USA). The gene-speci¢c primers SN-2S and SN-3S
were used for 3P-RACE, and SN-5AS and SN-4AS for 5P-RACE ac-
cording to the manufacturer’s instructions. The fragments obtained
were cloned in pGEM T vector (Promega, Mannheim, Germany) and
subsequently sequenced. The speci¢city of the inserts for LEAP-1 was
veri¢ed by sequence comparisons using the MacMolly program pack-
age (Softgene).
2.5. Real-time RT-PCR analysis
To quantitatively evaluate the expression of the LEAP-1 gene in
various human tissues we performed real-time RT-PCR [16] by means
of a Prism 7700 Sequence Detection System (PE Biosystems). Primers
and probes were designed with the assistance of the Primer Express
software (PE Biosystems). The probe constructed £anked intron 2 of
the gene (FAM-CCAGCTGGATGCCCATGTTCCAGA-TAMRA)
while the PCR primers were speci¢c for exons 2 and 3. For relative
quanti¢cation, the values calculated for LEAP-1 gene expression in
each sample were divided by the corresponding values for the glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) housekeeping gene.
All quantitative real-time RT-PCR experiments were performed in
duplicate using standard reagents and mixes from PE Biosystems
and 96-well microplates containing cDNAs from 14 di¡erent human
tissues, six standard curve samples (prepared from HUH-7 cells) and
two non-template controls (puri¢ed water, ACS reagent, Sigma-Al-
drich).
3. Results and discussion
The peptide isolation procedure utilizing a mass spectro-
metric assay for cysteine-rich peptides (Fig. 1) resulted in
the isolation of a peptide which was shown to be homogene-
ous by HPLC and capillary electrophoretic analysis. Sequence
analysis revealed the amino acid sequence DTHFPIX-
IFXXGXXHRSKXGMXXKT (Fig. 2), where X represents
residues which gave blank cycles during Edman sequencing.
As a di¡erence in molecular mass between the original sample
and the reduced and subsequently carboxamidomethylated
sample corresponded to eight cysteine residues, it was con-
cluded that all Xs of the peptide sequence represent cysteine.
The corresponding sequence of the peptide containing eight
disul¢de-bonded cysteine residues would have a molecular
mass of 2789.3 Da. This value accords exactly with the mo-
lecular mass that was found experimentally for the isolated
peptide which we termed LEAP-1. To our knowledge, a pep-
tide containing four disul¢de bonds within a stretch of 17
amino acid residues is unique in the human proteome. In
the COOH-terminal moiety, LEAP-1 contains basic amino
acid residues such as lysine and arginine. Therefore, LEAP-
1 exhibits structural features which are known from other
peptide antibiotics such as the defensins [3,8]. To verify the
structure determined and to investigate antimicrobial e¡ects
of LEAP-1, a corresponding synthetic peptide was produced.
Oxidation of the reduced synthetic precursor readily produced
a major product identical with the native counterpart.
To determine the amino acid sequence of the precursor
protein and to investigate the expression pattern of the corre-
sponding gene, the cDNA speci¢c for LEAP-1 was cloned and
sequenced. For this purpose, sequence comparisons of the
LEAP-1 amino acid sequence with entries of the EMBL
data base were carried out. We could identify a putative
gene for LEAP-1 being located within a sequenced contig of
human chromosome 19 (accession number AD000684). From
the given nucleotide sequence of the gene we then deduced the
most probable exon regions by searching for typical exon/in-
Fig. 1. Comparison of MALDI-TOF mass spectra of peptide frac-
tions 7^30 before (upper trace) and after carboxamidomethylation
(lower trace). The mass shift of 464.5 Da indicates the content of
eight cysteine residues in LEAP-1 which was con¢rmed by Edman
degradation with the puri¢ed peptide.
FEBS 24035 28-8-00
A. Krause et al./FEBS Letters 480 (2000) 147^150148
tron boundary sequences and open reading frames. Following
this strategy, six PCR primers located within the putative
exons 1 and 3 of the LEAP-1 gene were derived. In PCR
reactions with cDNA from human lung, kidney, liver and
tonsils, we obtained homogeneous bands with each of the
possible nine primer combinations. The most homogeneous
and intensive band was obtained from human liver cDNA
and the primer combination SN-2S/SN-6AS. The PCR prod-
uct was cloned, sequenced and veri¢ed as LEAP-1-speci¢c. To
amplify the 3P- as well as the 5P-end of the LEAP-1 cDNA, we
performed nested 3P- and 5P-RACE PCR. The RACE PCR
products obtained exhibited comparable sizes and could both
be veri¢ed as LEAP-1-speci¢c. By identi¢cation of overlap-
ping regions and the largest fragments obtained, a 391 bp
LEAP-1-speci¢c cDNA sequence exactly matching the three
exon regions of the corresponding gene was ¢nally deter-
mined. Approximately 40 bp upstream of the 5P-terminal nu-
cleotide of the cDNA sequence, a potential TATA box motif
(ATAAAA) was identi¢ed within the above-mentioned contig.
Furthermore, a typical AATAAA polyadenylation signal is
located approximately 28 bp upstream of the 3P-terminus of
the cDNA. Both ¢ndings indicate the cloning of an almost
full-length cDNA speci¢c for LEAP-1.
The cDNA sequence exhibits an open reading frame encod-
ing an 84-residue precursor protein which contains the iso-
lated peptide at the COOH-terminus (Fig. 2). An NH2-termi-
nal signal sequence (residues 1^24) characteristic for secretory
proteins was identi¢ed using prediction methods [17]. In ad-
dition, a basic penta-arginyl segment directly adjacent to the
NH2-terminus of the isolated peptide is contained within the
precursor protein. It appears that the LEAP-1 precursor is a
secretory protein that is proteolytically processed at the poly-
basic proteolysis site whereby the isolated peptide LEAP-1 is
released. A further processing of LEAP-1 seems to be possible
as an NH2-terminally truncated form (sequence positions 65^
84) was also identi¢ed in human blood ultra¢ltrate by mass
spectrometry. With its eight cysteine residues forming four
disul¢de bonds along a sequence of 17 amino acids, LEAP-
1 is an exceptionally structured molecule. Interestingly, data
base comparisons using the entire amino acid sequence de-
rived from cDNA translation resulted in an entry (SwissProt,
P81172) describing the partial amino acid sequence 50^84 of
the LEAP-1 precursor. However, this entry does not provide
information regarding the occurrence of LEAP-1 in plasma
and the cysteine connectivity, gene expression and the antimi-
crobial activity. Furthermore, tBLASTn searches in the Gen-
Bank data base led to the identi¢cation of several mouse EST
clone sequence entries (e.g. W41260, W36480, W34077) re-
lated to LEAP-1. The corresponding murine cDNA encodes
a putative 84-residue protein which shows a sequence identity
of approximately 51% with human LEAP-1, and exhibits an
identical cysteine pattern at its COOH-terminus. Thus, it
might represent the murine ortholog of LEAP-1.
Using the synthetic peptide, we examined the antimicrobial
e¡ects of LEAP-1 by performing an agar di¡usion assay [11].
Here, mainly Gram-positive bacteria exhibited susceptibility
to LEAP-1 treatment (Fig. 3). Nevertheless, LEAP-1 also in-
hibited the growth of Gram-negative Neisseria cinerea and the
yeast Saccharomyces cerevisiae, thus resembling the antimicro-
bial spectrum of human L-defensin-1 [18]. In contrast, no in-
hibition of the growth of the yeast Rhodotorula rubra and
Gram-negative germs Escherichia coli BL21 and Pseudomonas
£uorescens was detected. In order to determine the in vitro
IC50 values of LEAP-1 against two sensitive strains, we per-
formed CFU assays. These experiments revealed half-maximal
inhibitory activity at approximately 40 Wg/ml (14.4 WM)
against B. subtilis and 50 Wg/ml (18 WM) against S. cerevisiae.
These e¡ective peptide concentrations are in the same order of
magnitude as known for other antimicrobial peptides [19^22].
Fig. 2. LEAP-1 precursor cDNA sequence and deduced amino acid
sequence. Coding regions are printed in capital letters. The positions
of the primers used for preparative RT-PCR and the positions of
the putative introns 1 and 2 within the corresponding gene are indi-
cated. The sequence representing the isolated antimicrobially active
LEAP-1 and the potential polyadenylation signal are underlined.
The typical secretory signal sequence 1^24 is printed in italics.
Fig. 3. Dose-dependent antibacterial activity of LEAP-1 using
the radial di¡usion assay. (A) Bacillus megaterium ATCC14581, (B)
Bacillus subtilis ATCC6051, (C) Micrococcus luteus ATCC9341,
(D) Staphylococcus carnosus DSM20501, (E) Neisseria cinerea
ATCC14685, (F) Saccharomyces cerevisiae ATCC9763. 1 inhibition
unit (U) corresponds to 0.1 mm radius of growth inhibitory area.
The results of two independent experiments with casocidin-I at 11
Wg as a positive control are shown. Casocidin-I has been shown to
cause antimicrobial e¡ects comparable to those of magainin II [18].
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Increased peptide concentrations due to local stimulation of
expression at in£ammatory sites or putative synergism be-
tween di¡erent antimicrobial components of suboptimal con-
centrations contribute to the fact that it is di⁄cult to conclude
in vivo e¡ects from in vitro assays. Moreover, it might be
possible for an antimicrobial peptide even in sublethal con-
centrations to be active against pathogens by receptor-medi-
ated interactions or other mechanisms [20,23,24].
In order to analyze whether the expression pattern of
LEAP-1 is similar to that of other human antibiotic peptides,
we performed quantitative real-time RT-PCR assays (Fig. 4).
The highest level of LEAP-1 gene expression was detected in
the liver where it was found in a range comparable to that of
the GAPDH housekeeping gene. Expression of LEAP-1 in
heart and brain proved to be at least two times higher than
in the other tissues tested. These organs have not been re-
ported so far to harbor signi¢cant amounts of antimicrobial
peptides. Lung, prostate gland, tonsils, salivary gland and
trachea express LEAP-1 in a similar but low level. These
results were con¢rmed using the superoxide dismutase gene
as housekeeping gene for quantitative real-time RT-PCR
and indicate a rather unusual expression pattern for an anti-
microbially active peptide. In particular, the prevailing expres-
sion in liver gives rise to further investigations concerning the
role of LEAP-1 in liver-speci¢c functions. Thus, it would be
important to evaluate whether LEAP-1 is involved in the ac-
tivation of liver-derived acute-phase proteins. However, sev-
eral ¢ndings suggest that antimicrobial peptides may have
further functions other than the direct inhibition of microbes
at mucosal barriers [23^25].
In conclusion, we identi¢ed a novel peptide that circulates
in human blood plasma and exhibits a unique motif of cys-
teine connectivity. LEAP-1 extends the known families of en-
dogenous peptides with growth inhibitory e¡ects on microbial
organisms. Future investigations concerning the role of
LEAP-1 should address the extraordinary level of expression
in the liver, and possible synergistic e¡ects with other compo-
nents of the immune system.
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Fig. 4. Expression of the LEAP-1 gene by real-time quantitative
RT-PCR. The indicated x-fold expression of LEAP-1 in di¡erent
tissues was determined by standardization to the expression in the
kidney, using a two-step calculation method. First, averaged LEAP-
1 expression values of each tissue were divided by the values for the
GAPDH housekeeping gene. Then, the normalized target gene val-
ues obtained were divided by the normalized calibrator value. Tissue
from kidney with the lowest LEAP-1 expression level served as cali-
brator (i.e. kidney exhibits a 1-fold expression). For all tissues three
experiments were carried out in duplicate.
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